603207 小方制药
2024/06 - 中期2023/122022/122021/12

盈利能力分析
净资产收益率 ROE (%)18.57842.76558.251110.226--
总资产报酬率 ROA (%)15.28734.63241.25265.419--
投入资产回报率 ROIC (%)18.53542.57356.712104.089--

边际利润分析
销售毛利率 (%)66.56165.46359.03763.350--
营业利润率 (%)53.18950.05245.16538.494--
息税前利润/营业总收入 (%)52.42249.95044.93738.427--
净利润/营业总收入 (%)45.38643.15338.34231.428--

收益指标分析
经营活动净收益/利润总额(%)100.53297.43396.21092.149--
价值变动净收益/利润总额(%)0.0110.9501.4421.859--
营业外收支净额/利润总额(%)-0.2230.417-0.142-0.070--

偿债能力分析
流动比率 (X)3.6903.4203.6442.098--
速动比率 (X)3.4053.0433.0091.755--
资产负债率 (%)16.95018.62019.62840.650--
带息债务/全部投入资本 (%)0.1690.1640.4905.003--
股东权益/带息债务 (%)59,055.38360,752.81620,243.3071,887.685--
股东权益/负债合计 (%)489.957437.052409.475146.004--
利息保障倍数 (X)-80.739-160.364-273.748-975.398--

营运能力分析
应收账款周转天数 (天)69.16363.80554.19549.897--
存货周转天数 (天)93.020118.297106.348130.490--